Gilead Sciences Inc (GILD)vsLive Nation Entertainment Inc (LYV)
GILD
Gilead Sciences Inc
$138.26
+0.11%
HEALTHCARE · Cap: $171.45B
LYV
Live Nation Entertainment Inc
$154.92
+1.45%
COMMUNICATION SERVICES · Cap: $35.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 17% more annual revenue ($29.44B vs $25.20B). GILD leads profitability with a 28.9% profit margin vs 2.0%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).
GILD
Strong Buy72
out of 100
Grade: B
LYV
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.9%
Fair Value
$299.95
Current Price
$138.26
$161.69 discount
Intrinsic value data unavailable for LYV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 37.4%
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Earnings expanding 23.4% YoY
Every $100 of equity generates 37 in profit
Areas to Watch
4.7% revenue growth
2.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Trading at 133.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : LYV
The strongest argument for LYV centers on Return on Equity. Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : GILD
The primary concerns for GILD are Revenue Growth.
Bear Case : LYV
The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 2.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
LYV carries more volatility with a beta of 1.15 — expect wider price swings.
LYV is growing revenue faster at 11.1% — sustainability is the question.
GILD generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GILD scores higher overall (72/100 vs 47/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Live Nation Entertainment Inc
COMMUNICATION SERVICES · ENTERTAINMENT · USA
Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?